BPA for ampyra and inbrijia
Active Awarded Last action
- Contract number
- 36E79725A0009
- Awardee
-
Merz Pharmaceuticals, LLC UEI UMD1NK9KU143
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 81% complete
- IDV ceiling
- $12,057,300.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
Merz Pharmaceuticals, LLC has been awarded a single-award Blanket Purchase Agreement by the National Acquisition Center, a civilian federal agency, for the supply of two specialized pharmaceutical products: Ampyra and Inbrijia. The BPA, established under the General Services Administration Federal Supply Schedule 61-IB (Pharmaceuticals and Drugs), carries a ceiling value of $12,057,300.00 and is currently in its first option year following the initial award on March 13, 2025. The contract vehicle operates through March 12, 2027, providing federal agencies with streamlined access to these pre-negotiated pharmaceutical products under established pricing and terms. No small business set-aside was utilized for this procurement, reflecting the single-award structure and the specialized nature of the pharmaceutical products involved.
Ampyra (dalfampridine) and Inbrijia (tirzepatide) represent distinct therapeutic categories within the pharmaceutical market. Ampyra is approved for enhancing walking ability in individuals with multiple sclerosis, while Inbrijia is a glucagon-like peptide-1 receptor agonist indicated for weight management and glycemic control. The BPA structure enables federal healthcare providers, including Veterans Health Administration facilities and Defense Health Agency-supported organizations, to procure these critical pharmaceutical supplies efficiently while leveraging the pre-negotiated pricing established under the GSA Federal Supply Schedule. This indefinite delivery vehicle supports mission-critical healthcare needs across the federal government while maintaining cost-effectiveness through consolidated procurement mechanisms.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79725A0009?
36E79725A0009 was awarded to Merz Pharmaceuticals, LLC by National Acquisition Center (Headquarters) on March 13, 2025.
How much is contract 36E79725A0009 worth?
36E79725A0009's own ceiling is $12,057,300.
Who can order from contract 36E79725A0009?
36E79725A0009 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79725A0009 under another contract?
Yes. 36E79725A0009 is a blanket purchase agreement under 36F79719D0246, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79725A0009 competed?
The extent of competition for 36E79725A0009 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV